Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Liminal BioSciences, Inc. operates as a clinical stage biopharmaceutical company. The firm focuses on developing distinctive novel small molecule therapeutics for inflammatory, fibrotic, and metabolic diseases using drug discovery platform and a data driven approach. The firm has business operations in Canada and the United Kingdom. Its small molecule product candidate, fezagepras, has completed a Phase 1 multi-ascending dose clinical trial and anticipate conducting a comparative Phase 1a single ascending dose clinical trial to provide comparative data to support development plan. The company was founded on October 14, 1994 and is headquartered in Laval, Canada.
No news articles found for Liminal BioSciences.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.